Alzheimers Memory Center — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$44,598	4
2024	Research	$586,337	36
2023	Research	$651,430	3
2022	Research	$342,507	4
2021	Research	$572,565	3
2020	Research	$301,518	40
2019	Research	$645,915	176

Breakdown

Who paid Research payments · program years 2019–2025

Biogen, Inc. $2,011,006 10 payments
Genentech, Inc. $512,207 15 payments
Eisai Inc. $404,525 197 payments
GlaxoSmithKline, LLC. $119,679 31 payments
Eli Lilly and Company $47,594 9 payments
E.R. Squibb & Sons, L.L.C. $44,877 1 payment
Merck Sharp & Dohme Corporation $4,982 3 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease $977,696 4 payments
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 $571,351 1 payment
Gantenerumab in Early Ad $472,047 9 payments
Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $304,447 1 payment
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $190,536 111 payments
Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $148,541 3 payments
A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlle $119,679 31 payments
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $94,613 53 payments
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $67,015 4 payments
Phase 2 PoC in Early AD Patients - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer s Disease (TargetT $44,877 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.